Zelasudil Drug Asset Due Diligence Report 2026

This Zelasudil Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Zelasudil can convert its Small molecule drug profile and ROCK2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Zelasudil (query alias: Zelasudil)
Modality / target	Small molecule drug; ROCK2; ROCK2 inhibitors
Highest global status	Phase 2
Originator	Redx Pharma Plc
Active developers	Redx Pharma Plc

The MCP disease footprint includes Idiopathic Pulmonary Fibrosis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05570058	Phase 2	Active, not recruiting	48	Primary endpoint not disclosed in English source
NCT04931147	Phase 1	Completed	90	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Redx presents encouraging signal searching data for zelasudil (RXC007) as a well-tolerated treatment for Idiopathic Pulmonary Fibrosis at ERS

Phase 2; n=48; evaluation: Positive. Reported fields: FVC(12-week) = Zelasudil was shown to numerically reduce FVC decline when compared to placebo at 12 weeks with a 47% reduction in FVC decline (58ml) for patients dosed at 20mg BID and a corresponding 13% reduction in FVC decline (16ml) at 50mg BID. ; FVC(12-week) = Zelasudil was shown to numerically reduce FVC decline when compared to placebo at 12 weeks with a 47% reduction in FVC decline (58ml) for patients dosed at 20mg BID and a corresponding 13% reduction in FVC decline (16ml) at 50mg BID.

Redx Presents Encouraging Phase 1 Safety Data for RXC007

Phase 1; n=not disclosed; evaluation: Positive. Reported fields: SAE = none in the multiple dose phase (dosed at 50mg twice daily for 14 days)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Zelasudil addresses Idiopathic Pulmonary Fibrosis. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 12 matched transaction record(s) under the scope “target-level comparable: ROCK2.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: ROCK2 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-03-04	Sino biopharm unit licenses blood cancer drug to sanofi for up to $1.53 billion	Approved	Financial terms not disclosed
2025-09-16	AllRock gained rights to ROC-101 from Sanofi	Phase 2	Financial terms not disclosed
2023-11-01	Transaction title not available in English source	Phase 2	US$45.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Culture medium for differentiating neurons from stem cells and differentiation method”. The milestone feed surfaced a patent-application signal described as “Therapy for treating type 1 diabetes using rock2 and DYRK1 inhibitors”. The milestone feed surfaced a patent-application signal described as “Modulators of Rho-associated Protein Kinase”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO